...
首页> 外文期刊>Molecular Biology >A Novel Gene P28GANK Confers Multidrug Resistance by Modulating the Expression of MDR-1, Bcl-2, and Bax in Osteosarcoma Cells
【24h】

A Novel Gene P28GANK Confers Multidrug Resistance by Modulating the Expression of MDR-1, Bcl-2, and Bax in Osteosarcoma Cells

机译:一个新的基因P28GANK通过调节骨肉瘤细胞中MDR-1,Bcl-2和Bax的表达赋予多重耐药性

获取原文
获取原文并翻译 | 示例
           

摘要

As previously reported, a novel gene P28GANK conferred a multidrug resistant phenotype in gastric cancer cells. The aim of this study was to explore the role of P28GANKm the development of multidrug resistance (MDR) in osteosarcoma cells. P28GANKgene was found to be overexpressed at the mRNA level and the protein level in a cisplatin induced MDR osteosarcoma cell line Saos-2/CDDP compared to its parent cell line Saos-2. Here, we transfected the osteosarcoma cell line Saos-2 with eukaryotic expression vector of P28GANK. In vitro drug sensitivity assay suggested that Saos-2-P28GANK cells conferred resistance to both P-glycoprotein (P-gp)-related and P-gp-nonrelated drugs. Blocking P28GANK expression in MDR osteosarcoma cells Saos-2/CDDP by P28GANK-specific small interfering RNA (siRNA) increased the cell sensitivity to various chemotherapeutic drugs. Flow cytometry examination suggested that P28GANK gene expres-' sion could suppress Adriamycin-induced apoptosis accompanied by decreased accumulation and increased release of Adriamycin. Semiquantitative RT-PCR", Western blot and Luciferase reporter assay suggested that P28GANK gene could significantly up-regulate the expression of MDR-1 and Bcl-2, transcription of the MDR-1 gene and down-regulate the expression of Bax. In addition, inhibition of P28GANK expression by RNA interference or P-gp inhibition could partially reverse P28GANK-mediated MDR. Taken together, our findings suggest that down-regulation of P28GANK gene expression could sensitize osteosarcoma cells to chemotherapeutic drugs by down-regulation of the MDR-1 and Bcl-2 and up-regulation of Bax gene expression, without altering the glutathione S-transferase activity, or intracellular glutathione content in osteosarcoma cells. Further study on biological function of P28GANK may be helpful for understanding MDR mechanism of osteosarcoma and developing a strategy for osteosarcoma treatment.
机译:如先前报道的,新基因P28GANK在胃癌细胞中赋予了多药耐药表型。这项研究的目的是探讨P28GANKm在骨肉瘤细胞中发展多药耐药性(MDR)的作用。与它的亲代细胞系Saos-2相比,在顺铂诱导的MDR骨肉瘤细胞系Saos-2 / CDDP中发现P28GANKgene在mRNA水平和蛋白质水平上过表达。在这里,我们用P28GANK的真核表达载体转染了骨肉瘤细胞Saos-2。体外药物敏感性测定表明,Saos-2-P28GANK细胞赋予对P-糖蛋白(P-gp)相关和P-gp不相关药物的抗性。通过P28GANK特异性小干扰RNA(siRNA)阻断MDR骨肉瘤细胞Saos-2 / CDDP中的P28GANK表达,增加了细胞对各种化疗药物的敏感性。流式细胞仪检查表明,P28GANK基因表达可以抑制阿霉素诱导的细胞凋亡,并伴有阿霉素的积累减少和释放增加。 “半定量RT-PCR”,Western印迹和荧光素酶报告基因检测结果表明,P28GANK基因可以显着上调MDR-1和Bcl-2的表达,MDR-1基因的转录并下调Bax的表达。总的来说,RNA干扰抑制P28GANK表达或P-gp抑制可以部分逆转P28GANK介导的MDR,我们的发现表明P28GANK基因表达的下调可以通过MDR-下调来使骨肉瘤细胞对化疗药物敏感。 1和Bcl-2以及Bax基因表达的上调而不改变骨肉瘤细胞中的谷胱甘肽S-转移酶活性或细胞内谷胱甘肽含量,进一步研究P28GANK的生物学功能可能有助于了解骨肉瘤的MDR机制和发展骨肉瘤的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号